Tagraxofusp approved for use in EU for the treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

This targeted therapy directed to CD123 was approved as a monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm a rare, aggressive haematologic malignancy. It is the first approved treatment for this condition.

Source:

Biospace Inc.